Conflict of Interest
TG
CROSS
John L. Reagan reported consulting/advisory relationships with Rigel, Pfizer, and Bristol Myers Squibb. Adam J. Olszewski reported consulting/advisory relationships with TG Therapeutics, Genmab, Schrodinger, and Blue Cross and Blue Shield of Rhode Island, research funding from Adaptive Biotechnologies, Genentech/Roche, TG Therapeutics, Spectrum Pharmaceuticals, Celldex, Precision Biosciences, and Genmab. Eric S. Winer reported consulting/advisory relationships with for Jazz Pharmaceutical, Pfizer, Takeda, Novartis, and Curis. The other authors indicated no financial relationships.